iDose TR Generic: When Will Generic Travoprost Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
iDose TR Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? February 2031 About 4.5 years away Why then?
- Has the FDA approved a generic? March 2013 7 companies approved
- When does the last patent end? February 2031 4 patents listed with the FDA
- Can you buy a generic today? Yes 5 companies list one in some form
A generic matching iDose TR is expected to be available in February 2031, about 4.5 years away. A generic travoprost is already listed for sale in some form by 5 companies, so ask your pharmacy whether one matches iDose TR.
Why February 2031?
It is when iDose TR’s patent 12,201,555 ends. That patent covers the active ingredient and the product’s formulation, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
Will the generic cost less?
Usually. The FDA has already approved 7 companies to make a generic, and how many of them launch decides how far the price falls. See the price pattern
What should I do now?
Ask your pharmacy whether it can fill your prescription with a generic. It may look different from iDose TR, but the active ingredient, strength and form are the same. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
iDose TR by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- None filed yet No filers on record
- Brand sales
- Sales not reported
- FDA approved 2023 December 2023 FDA Orange Book
- Patents listed 4 last runs to February 2031 FDA Orange Book
- Generics FDA-approved 7 companies, the first approved March 2013 FDA Orange Book
- Medicaid prescriptions 15 in the last four reported quarters, $53.1K CMS Medicaid drug utilization, to Q4 2025
iDose TR’s Road to a Generic
iDose TR has had the market to itself since the FDA approved it in December 2023 (Glaukos Corp). Its FDA protection (new product) runs to December 2026. Its 4 listed patents run to February 2031.
The first generic of iDose TR is expected in February 2031.
Why that month: patent 12,201,555, on the active ingredient and the product’s formulation, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
iDose TR Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for iDose TR’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 12,201,555, which ends in February 2031, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 12,201,557 | The active ingredient; the product’s formulation; a way of using it (U-4129) | June 2030 | Active |
| 10,206,813 | The product’s formulation | October 2030 | Active |
| 11,426,306 | The product’s formulation | October 2030 | Active |
| 12,201,555 Sets the expected month of generic availability | The active ingredient; the product’s formulation | February 2031 | Active |
| Exclusivity | What it means | Ends | Status |
|---|---|---|---|
| New product NP | Three years of protection for a change that needed new clinical studies. | December 2026 | Active |
Source: FDA Orange Book, application 218010. Patent numbers open the patent on Google Patents.
Who Is Lined Up to Make Generic Travoprost
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
No application count is on record for iDose TR, but the FDA has already approved 7 companies (step 2), and every approval starts with an application.
The FDA has tentatively approved one company’s generic: Par Pharm (August 2011). A tentative approval means the generic is ready, but a patent or exclusivity still stops the FDA from giving it final approval.
Approved by the FDA
The FDA has approved generic versions from 7 companies, the first in March 2013. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
For Sale in Pharmacies
Yes. A generic travoprost in some form is listed for sale by 5 companies. Ask your pharmacy whether it can fill your prescription with it.
Apotex Corp., Bryant Ranch Prepack, Golden State Medical Supply, Inc., Sagent Pharmaceuticals and Sandoz Inc
| Company | First approved | Strengths | Rated |
|---|---|---|---|
| Chartwell Rx Sciences LLC | March 2013 | 0.004% | – |
| Apotex Inc | July 2015 | 0.004% | AT2 |
| Mylan Pharmaceuticals Inc | July 2017 | 0.004% | AT2 |
| Alembic Pharmaceuticals Ltd | December 2019 | 0.004% | AT2 |
| Micro Labs Ltd | March 2021 | 0.004% | AT2 |
| Gland Pharma Ltd | July 2024 | 0.004% | AT2 |
| Somerset Therapeutics LLC | September 2024 | 0.004% | AT2 |
| Lupin Ltd discontinued | May 2024 | 0.004% | – |
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
iDose TR Price: What Pharmacies Pay and What Generics Usually Do
What a Generic Could Cost
How we estimate it. The national survey of what pharmacies pay (NADAC) has no recent price for iDose TR, so we cannot show dollars. Here is the FDA’s finding of how far the price pharmacies pay usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017).
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on iDose TR
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicaid Prescriptions by Quarter
15 prescriptions in the four quarters to Q4 2025, $53.1K paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q4 2025 | 0 | $0 |
| Q3 2025 | 15 | $53,144 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
Source: CMS Medicaid State Drug Utilization Data, over iDose TR’s own package codes.
iDose TR Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| 75MCG | Implant | Intracameral | December 2023 | Prescription reference product |
Source: FDA Orange Book, Glaukos Corp. Listed for sale today by Glaukos Corporation (FDA NDC Directory).
iDose TR NDC Codes and Packages
Each iDose TR package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 25357-0100-01 | TRAVOPROST 75 ug/1 implant | canister of 1 implant | Glaukos Corporation |
| 25357-0100-01 | TRAVOPROST 75 ug/1 implant | canister of 1 implant | Glaukos Corporation |
| 25357-0100-99 | TRAVOPROST 75 ug/1 implant | canister of 1 implant | Glaukos Corporation |
Source: the FDA NDC Directory, current listings only. Only packages sold under iDose TR’s own FDA approval (NDA 218010) are listed, never a generic. Some codes belong to companies that repackage iDose TR: it is the same medicine in a different package.
What a Generic iDose TR Means for You
Nothing Changes Until It Is in Pharmacies
A generic is listed for sale now, so your pharmacy may already be able to fill your prescription with it.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Questions people ask about iDose TR
Is there a generic for iDose TR right now?
Yes. The FDA NDC Directory lists a generic travoprost in some form from 5 companies. Ask your pharmacy whether it can fill your prescription with it.
When will iDose TR go generic?
February 2031 is the expected month, and that is probable but not certain. It is when iDose TR’s patent 12,201,555 ends. That patent covers the active ingredient and the product’s formulation, and once it ends, generics can go on sale as soon as the FDA approves them.
Will generic travoprost be the same as iDose TR?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. The FDA has already approved 7 companies to make a generic, and how many of them launch decides how far the price falls.
Has the FDA approved a generic iDose TR?
Yes. The FDA Orange Book lists approved generic versions from 7 companies, the first approved in March 2013: Chartwell Rx Sciences LLC, Apotex Inc, Mylan Pharmaceuticals Inc, Alembic Pharmaceuticals Ltd and 3 more. Approved is not the same as on sale: patents, a settlement or the company’s own plans can still hold a launch.
When does the iDose TR patent expire?
The FDA Orange Book lists 4 patents for iDose TR; the last runs to February 2031. The one behind the expected month is patent 12,201,555, which ends in February 2031. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (February 2031) weighs all of that.
Changes to This Projection
- First generic expected February 2031 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- SynriboOmacetaxine MepesuccinateOctober 2026
- XepiOzenoxacinJanuary 2032
- BeizrayDocetaxelMay 2036
- KrazatiAdagrasibMay 2037
- OxlumoLumasiran2038 to 2039
- EvdiTrabectedinFebruary 2043
About iDose TR
- Generic name travoprost
- How it is taken Implant
- Company Glaukos Corp
- Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
- More drugs Brand-name drugs starting with I
- Have a question? A pharmacist answers, free. Ask about iDose TR
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.